Skip to content

EBIT at other companies

LivaNova logo
LivaNovaLIVN
$41.47M-14.7%
ICU Medical logo
ICU MedicalICUI
$13.58M+5.4%
OSI Systems logo
OSI SystemsOSIS
$53.21M-5.3%
Edwards Lifesciences logo
Edwards LifesciencesEW
United Therapeutics logo
United TherapeuticsUTHR

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Calculated from TransMedics Group, Inc.’s reported figures.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s EBIT?
TransMedics Group, Inc. (TMDX) reported EBIT of $13.3M in Q1 2026.
How has TransMedics Group, Inc.'s EBIT changed year-over-year?
TransMedics Group, Inc.'s EBIT decreased by 51.5% year-over-year, from $27.44M to $13.3M.
What is the long-term trend for TransMedics Group, Inc.'s EBIT?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s EBIT has grown at a 28.8% compound annual growth rate (CAGR), from -$39.43M to $108.58M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.